July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Evaluating retinal biomarkers in a mouse model of Parkinson’s disease
Author Affiliations & Notes
  • Christine Tram Oanh Nguyen
    Optometry and Vision Sciences, University of Melbourne, Parkville, Victoria, Australia
  • Katie Tran
    Optometry and Vision Sciences, University of Melbourne, Parkville, Victoria, Australia
  • Jeremiah Kah Heng Lim
    Optometry and Vision Sciences, University of Melbourne, Parkville, Victoria, Australia
  • Vickie Hoi Ying Wong
    Optometry and Vision Sciences, University of Melbourne, Parkville, Victoria, Australia
  • Ali Shahandeh
    Optometry and Vision Sciences, University of Melbourne, Parkville, Victoria, Australia
  • Algis J Vingrys
    Optometry and Vision Sciences, University of Melbourne, Parkville, Victoria, Australia
  • Bang V Bui
    Optometry and Vision Sciences, University of Melbourne, Parkville, Victoria, Australia
  • David Finkelstein
    Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia
  • Footnotes
    Commercial Relationships   Christine Nguyen, None; Katie Tran, None; Jeremiah Lim, None; Vickie Wong, None; Ali Shahandeh, None; Algis Vingrys, None; Bang Bui, None; David Finkelstein, None
  • Footnotes
    Support  Australian Research Council Linkage LP160100126; ); Melbourne Neuroscience Institute Interdisciplinary Seed Fund; ); Melbourne Research Fellowship
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3100. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christine Tram Oanh Nguyen, Katie Tran, Jeremiah Kah Heng Lim, Vickie Hoi Ying Wong, Ali Shahandeh, Algis J Vingrys, Bang V Bui, David Finkelstein; Evaluating retinal biomarkers in a mouse model of Parkinson’s disease. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3100.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The retina, an accessible outpouching of the central nervous system, may manifest cortical changes that occur with Parkinson’s disease (PD), lending itself as a potential biomarker. PD is characterised by reduced dopamine levels, a neurotransmitter found in amacrine cells. Human PD patients have also shown structural changes in the outer retina. This work aims to determine if retinal function and structure are altered in a murine model of PD and whether deficits can be ameliorated with L-DOPA treatment.

Methods : A PD model was induced in adult C57BL6/J mice using MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 4x i.p. injections, 20mg/kg) and vehicle control and examined at day 21 and 45. Another MPTP group was administered L-DOPA (L-3,4-dihydroxyphenylalanine 0.2 mg/ml) or control in their drinking water and assessed at day 45 (n=12–15/group). In ketamine:xylazine anaesthetised (80:10mg/kg) mice full-field dark- and light-adapted electroretinography (ERG) was assessed to target dopamine-related responses. Optical coherence tomography (OCT) was used to quantify thickness of retinal layers. Retinal and cortical tissue were collected for immunohistochemical assessment of changes in tyrosine hydroxylase (TH)and imaged using confocal microscopy. Data (mean±SEM) were compared using unpaired ANOVA and t-tests as appropriate.

Results : At day 21 no retinal changes were found. At day 45 dark and light adapted ERGs showed slower amacrine cell responses (oscillatory potential, p<0.05), a finding which reversed with L-DOPA treatment (p<0.05). Other components of the ERG were unchanged. TH staining showed a trend towards decreased retinal levels in MPTP mice but this did not reach significance (p=0.10). Reduced levels of TH were found in the ventral hippocampus of MPTP mice compared with control (p<0.05). OCT revealed thinning of the outer plexiform layer at day 45, and the L-DOPA group exhibited a thinning of the outer nuclear layer (p<0.05).

Conclusions : This study shows for the first time that the MPTP model recapitulates key dopaminergic changes previously reported in humans. In particular, electroretinographic changes that correspond with dopaminergic retinal cells occur in the Parkinson’s model and reverse with therapeutic treatment. Structural thinning of the outer retinal layers also occur, which parallels some human findings. This work paves the way for retinal measures as preclinical screening tools in drug development.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×